Effect of hormone replacement therapy on plasma lipoproteins and apolipoproteins, endothelial function and myocardial perfusion in postmenopausal women with estrogen receptor-α IVS1-397 C/C genotype and established coronary artery disease

Cardiology

Volumn 106, Issue 1, 2006, Pages 44-50

  Emre, Ayse ^a,c   Sahin, Sinan ^a   Erzik, Can ^b   Nurkalem, Zekeriya ^a   Oz, Dilaver ^a   Cirakoglu, Beyazit ^b   Yesilcimen, Kemal ^a   Ersek, Birsen ^a  

^a DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c NONE   (Turkey)

Author keywords

Endothelial function; Estrogen receptor polymorphism; Hormone replacement therapy; Perfusion

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; NITRATE; THALLIUM; TRIACYLGLYCEROL;

ADULT; AGED; ARTERY DIAMETER; ARTICLE; BRACHIAL ARTERY; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIUM CELL; ESTRADIOL BLOOD LEVEL; FEMALE; FOREARM BLOOD FLOW; GENETIC POLYMORPHISM; GENOTYPE; HEART MUSCLE PERFUSION; HORMONE SUBSTITUTION; HUMAN; HYPEREMIA; LIPOPROTEIN METABOLISM; PHENOTYPE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

APOLIPOPROTEINS; BRACHIAL ARTERY; CORONARY ARTERIOSCLEROSIS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENOTYPE; HORMONE REPLACEMENT THERAPY; HUMANS; LIPOPROTEINS; MIDDLE AGED; POLYMORPHISM, GENETIC; POSTMENOPAUSE; PROGESTERONE; VASODILATION;

EID: 33745713964     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092598     Document Type: Article

References (29)

1. Walsh BW, Schiff I, Rosner B, et al: Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-1204.
2. Sack MN, Rader DJ, Cannon RO: Estrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994;343:267-270.
3. Mijatovic V, Kenemans P, Jakobs C, van Baal WM, Peters-Muller ER, van der Mooren MJ: A randomized controlled study of the effects of 17 beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women. Obstet Gynecol 1998;91:432-436.
4. Zanger D, Yang BK, Ardans J, et al: Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol 2000;36:1797-802.
5. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M: Effects of oral and transdermal estrogen/progestin regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997;17:3071-3078.
6. Williams JK, Adams MR, Herrington DM, et al: Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol 1992;20:452-457.
7. Collins P, Rosano GMC, Sarrel PM, et al: Estradiol-17β attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995;92:24-30.
8. Guetta V, Quyyumi AA, Prasad A, et al: The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. Circulation 1997;96:2795-2801.
9. Grady D, Herrington D, Bittner V, et al: Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study Follow-up. JAMA 2002;288:49-57.
10. Herrington DM, Reboussin DM, Brosnihan KB, et al: Effects of estrogen replacement on the progression of coronary atherosclerosis. N Engl J Med 2000;343:522-529.
11. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288:321-333.
12. Herrington DM, Howard TD, Hawkins GA, et al: Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 2002;346:967-974.
13. Herrington DM, Howard TD, Brosnihan B, et al: Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 2002;105:1879-1882.
14. Herrington DM, Howard TD: ER-α variants and the cardiovascular effects of hormone replacement therapy. Pharmacogenomics 2003;4:269-277.
15. John SWM, Weitzner G, Rozen R, Scriver CR: A rapid procedure for extracting genomic DNA from leukocytes. Nucleic Acids Res 1988;19:408-411.
16. Deng HW, Li J, Li JL, et al: Association of estrogen receptor-alpha genotypes with body mass index in normal healthy postmenopausal Caucasian women. J Clin Endocrinol Metab 2000;85:2748-2751.
17. Celermajer DS, Sorensen KE, Gooch VM, et al: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-1115.
18. Joannides R, Haefeli WE, Linder L, et al: Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995;91:1314-1319.
19. Kiat H, Berman DS, Maddahi J, et al: Late reversibility of tomographic thallium-201 defects: an accurate marker of myocardial viability. J Am Coll Cardiol 1988;12:1456-1463.
20. Berman KS, Kiat H, Friedman TD, et al: Separate acquisition rest thallium/stress technetium 99m sestamibi dual isotope myocardial perfusion single-photon computerized tomography: a clinical validation study. J Am Coll Cardiol 1993;22:1455-1464.
21. Piantadosi S: Clinical Trials: A Methodologic Perspective. New York, Wiley-Interscience, 1997, pp 404-418.
22. Lehrer S, Rabin J, Kalir T, Schachter BS: Estrogen receptor variant and hypertension in women. Hypertension 1993;21:439-441.
23. Matsubara Y, Murata M, Kawano K, et al: Genotype distribution of estrogen receptor polymorphisms in men and postmenopausal women from healthy and coronary populations and its relation to serum lipid levels. Arterioscler Thromb Vasc Biol 1997;17:3006-3012.
24. Koh KK, Schenke WH, Waclawiw MA, Csako G, Cannon RO: Statin attenuates increase in CRP during estrogen replacement therapy in postmenopausal women. Circulation 2002;105:1531-1535.
25. Williams JK, Adams MR, Herrington DM, Clarkson TB: Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol 1992;20:452-457.
26. Lieberman EH, Gerhard MD, Uehata A, et al: Estrogen improves endothelium-dependent flow mediated vasodilation in postmenopausal women. Ann Intern Med 1994;121:936-941.
27. Lu Y-Q, Figtreee G, Webb CM, Collins P: Effect of 17 beta estradiol on progesterone-induced relaxation in rabbit coronary arteries. Eur Heart J 1998;19(suppl):681.
28. Alexandersen P, Haarbo J, Sandholdt I, Shalmi M, Lawaetz H, Christiansen C: Norethindrone acetate enhances the antiatherogenic effect of 17 beta estradiol. A secondary prevention study of aortic atherosclerosis in ovariectomized cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1998;18:902-907.
29. Hasdai D, Gibbons RJ, Holmes DR, Higano ST, Lerman A: Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. Circulation 1997;96:3390-3395.